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eduction of “No-Reflow” Phenomenon by
ntra-Aortic Balloon Counterpulsation in a Randomized
agnetic Resonance Imaging Experimental Study
uciano C. Amado, MD,* Dara L. Kraitchman, VMD, PHD,† Bernhard L. Gerber, MD,*
rnesto Castillo, MD,† Raymond C. Boston, PHD,‡ Joseph Grayzel, MD,§ Joa˜o A. C. Lima, MD, FACC*
altimore, Maryland; Kennett Square, Pennsylvania; and Mahwah, New Jersey
OBJECTIVES Intra-aortic balloon counterpulsation (IABC) can improve post-myocardial infarction (MI)
outcomes, but the mechanisms of such effect remain unclear. We hypothesized that IABC
augmentation reduces the extent of microvascular obstruction after acute infarction.
BACKGROUND Microvascular obstruction or “no-reflow” (MO) has been shown to negatively influence left
ventricular (LV) remodeling after myocardial infarction (MI).
METHODS Seventeen dogs underwent 90 min of coronary artery occlusion followed by reperfusion.
Animals were then randomized to either IABC (n  9) or control (n  8); IABC
augmentation was performed for 24 h after MI. Microvascular obstruction and infarct size by
first-pass and delayed contrast-enhanced magnetic resonance imaging (MRI) were measured
at 1 and 24 h after reperfusion and compared with postmortem infarct size and MO by
microspheres.
RESULTS Microvascular obstruction by MRI, expressed as percent LV mass, decreased significantly in
IABC (4.9 2.2% to 3.6 1.5%) and increased in controls (3.4 0.5% to 4.9 1.1% from
1 to 24 h, respectively; p  0.001). Similar results were found for MO defined by
microspheres. In the control group, MO increased significantly, during 24 h of study (from
8.8  1.7% to 43.2  11.1% of infarcted myocardium; p  0.05), whereas not important
change was observed in the IABC group (from 21.3  7.1% to 25.8  14.7%; p  0.05 vs.
control at 24 h). Infarct size, measured by MRI, increased in both groups (13.2  1.8 to 15.5
 2.1 from 1 to 24 h, respectively; p  0.05).
CONCLUSIONS Intra-aortic balloon counterpulsation augmentation performed after reperfusion improves
myocardial perfusion at the tissue level, and reduces the extent of no-reflow caused by
microvascular obstruction. (J Am Coll Cardiol 2004;43:1291–8) © 2004 by the American
College of Cardiology Foundationi
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reperfusion therapy significantly improves survival after
cute myocardial infarction (MI) (1). Yet, despite flow
estoration in epicardial coronary arteries, limited reperfu-
ion at the tissue level due to microvascular obstruction
MO) has been documented, and is also known as the
no-reflow phenomenon” (2). Previous work has also dem-
nstrated that this is a progressive process, which evolves
ainly within the first 48 h after reperfusion (3). At the
ame time, continued ischemia due to MO, even after
uccessful reperfusion (4), has been proposed as a mecha-
ism of myocardial infarct extension (3), and has a negative
rognostic impact in patients with acute MI (5). This
uggests that there might be a therapeutic window for
ntervention to limit infarct extension by reducing the extent
f MO during the immediate reperfusion period. Such an
From the *Departments of Medicine, Division of Cardiology, and †Radiology,
ohns Hopkins University, School of Medicine, Baltimore, Maryland; ‡School of
eterinary Medicine, University of Pennsylvania, Kennett Square, Pennsylvania; and
Datascope Corporation, Mahwah, New Jersey. Funded by NIH NHLBI RO1-
L63439 and RO1-HL66075-01, Datascope Corporation. Dr. Amado was sup-
orted, in part, by a fellowship grant from Sociedade Brasileira de Cardiologia
SBC/FUNCOR).
Manuscript received August 18, 2003; revised manuscript received November 3,
i003, accepted November 18, 2003.ntervention could, in theory, result in better functional
utcomes and improved prognosis for post-MI patients.
Intra-aortic balloon counterpulsation (IABC) is a me-
hanical cardiac-assist device that significantly increases
iastolic and mean blood pressure in the aorta and coronary
rteries, while at the same time decreasing systolic pressure,
hereby unloading the heart. Intra-aortic balloon counter-
ulsation has been shown to improve survival in patients
ith acute MI who present with cardiogenic shock (6). In
atients with large acute infarcts, IABC has been shown to
mprove clinical outcomes (7–9). However, the mechanisms
nderlying the beneficial effects of IABC at the myocardial
issue level remain unknown. It is not known, for example,
hether IABC has a direct impact on the adequacy of
ost-MI reperfusion, and whether such effects are mediated
y reducing the progression of microvascular obstruction,
nfarct size, or both.
In this study, we tested the hypothesis that IABC
ugmentation has a beneficial effect on microvascular func-
ion after acute MI and epicardial coronary flow restoration.
e performed a randomized trial in a canine model of
eperfused MI using contrast-enhanced magnetic resonance
maging (MRI) to measure the impact of IABC therapy on
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nfarct size during the first 24 h after reperfusion.
ETHODS
xperimental protocol. All animal studies were approved
y our institutional animal care and use committee and
omply with the “Guide for the Care and Use of Laboratory
nimals” (NIH Publication no. 80-23, revised 1985). Sev-
nteen mongrel dogs (25 to 30 kg) were anesthetized,
ntubated, and mechanically ventilated. During the 24-h
eriod of study, all animals received prophylaxis with
ntibiotics (cefazolin, every 4 h) and were maintained under
eneral anesthesia with isofluorane 1% or 2%.
xperimental MI. Catheter sheaths were placed in the
ight femoral artery (10 F) and right carotid artery (8 F).
ubsequently, the animals were heparinized (5,000 IU
ntravenously). A 6 F pigtail catheter was advanced through
he femoral artery into the left ventricular (LV) cavity for
njection of radiolabeled microspheres and pressure moni-
oring. A coronary angioplasty balloon (3.5 F, 20 mm) was
dvanced through the right carotid artery into the proximal
eft anterior descending artery or left circumflex artery.
yocardial infarcts were created by inflating the angioplasty
alloon for 90 min, after which time the balloon was
eflated and the artery reperfused. After reperfusion, the
atheter sheath in the carotid artery was removed, and the
arotid artery permanently closed. The catheter sheath in
he femoral artery was maintained throughout the entire
tudy in every animal, regardless of the randomization
roup. No problems related to excessive bleeding or hema-
oma formation on the site of the incision was observed.
ABC randomization. After angioplasty balloon inflation
ut prior to reperfusion, each animal was randomized to either
he “control” or the “IABC” group. To achieve the best
ugmentation with this device, a pilot study was conducted,
sing intra-aortic balloons containing no ferromagnetic mate-
ials, especially designed for this study. In four animals,
ifferent balloon sizes and different methods of pumping were
ested. As a final result from the pilot study, the IABC group
eceived an intra-aortic balloon (40 cc, Datascope, Mahwah,
ew Jersey) inserted under X-ray fluoroscopy via the femoral
heath immediately before reperfusion. The tip of the intra-
ortic balloon was placed distal to the left subclavian artery, and
ABC augmentation commenced immediately after reperfu-
Abbreviations and Acronyms
IABC  intra-aortic balloon counterpulsation
LV  left ventricle/ventricular
MBF  myocardial blood flow
MI  myocardial infarction
MO  microvascular obstruction or “no-reflow
phenomenon”
MRI  contrast-enhanced magnetic resonance imaging
TTC  2,3,5-triphenyltetrazolium chlorideion for 24 h (triggered on electrocardiogram, 1:1). To avoid tny interference from the intra-aortic balloon augmentation, all
ata acquisition (imaging acquisition and microspheres blood
ample) was done with IABC off. All animals were heparinized
100 IU/h) and sedated throughout the entire study period.
adioactive microspheres. Myocardial blood flow (MBF)
as measured at baseline, during occlusion, and at 1 and
4 h after reperfusion, prior to euthanasia. For each mea-
urement,2 106 radioactive microspheres (15 to 16 m
iameter) labeled with 113Sn, 46Sc, 57Co, and 114Ru
PerkinElmer Inc., Wellesley, Massachusetts) were injected
nto the LV while an arterial blood sample was withdrawn.
RI protocol. Images were performed at 1 and 24 h after
eperfusion, using a 1.5-T magnetic resonance scanner
CV/i, GE Medical Systems). Animals were placed in right
ecubitus with a phased array surface coil wrapped around
he chest.
irst-pass perfusion imaging. Eight to 10 contiguous
hort-axis scout images were acquired covering the entire LV,
sing an electrocardiogram-gated, interleaved, saturation re-
overy gradient echocardiogram echoplanar imaging pulse
equence (EFGRET-ET) (10). Images were acquired contin-
ously for 1 min with intermittent breath-holds (30 s
uration), after an intravenous bolus of Gd-DTPA (0.1 mmol/
g, Magnevist, Berlex Inc., Montville, New Jersey). An entire
hort-axis stack was acquired every 2 to 4 heartbeats. After
ompletion of first pass image acquisition, a second bolus of
d-DTPA (0.1 mmol/kg) was injected.
elayed perfusion imaging. Images were acquired 15 min
fter the second contrast injection using an electrocardiogram-
ated, breath-hold, interleaved, inversion recovery, fast gra-
ient echocardiogram pulse sequence (11). Images were
cquired in the identical short-axis locations as the first-pass
erfusion images in mid-diastole.
RI data analysis. Magnetic resonance images were
ransferred to a SUN workstation (Sun Microsystems Inc.,
anta Clara, California) and analyzed using a custom
oftware package (MASS, Leiden, the Netherlands). No-
eflow regions were defined as regions that showed persis-
ent hypoenhancement for at least 1 min during the first 3
in after contrast injection (first-pass perfusion images) (3).
he magnitude of MO was estimated by measuring the
argest hypoenhanced area within the first minute after
ontrast injection. The decision was made by an agreement
f two observers blind to the randomization.
Hyperenhanced regions were defined as those having
istinct myocardial brightness on delayed images. The
orkstation window and level were set to full width and half
aximum, and the hyperenhanced region was traced to
etermine infarct size. Endocardial and epicardial contours
ere delineated on delayed images. The extent of infarct
ize and no-reflow by MRI was calculated as the sum of
egion-of-interest for all slices divided by the sum of the LV
ross-sectional areas for all slices. To minimize the influence
f the infarct swelling at 24 h, the measurements were given
s percentage of LV mass using the LV cross-sectional at
he respective time-point (1 and 24 h).
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April 7, 2004:1291–8 Intra-Aortic Balloon Benefit on AMIostmortem measurements. INFARCT SIZE. After eutha-
asia, the heart was excised, sectioned into short-axis slices (1
m thickness), and incubated in 2,3,5-triphenyltetrazolium
hloride (TTC) for 20 min at 38°C to delineate viable
yocardium. Each slice was photographed with a digital
amera. Using a custom software package (cine, GE Med-
cal Systems), TTC-negative areas and LV borders were
anually traced for each slice. Infarct size was determined
s a percentage of LV mass, given by measurements from
he digital pictures.
ICROSPHERE BLOOD FLOW ANALYSIS. To determine re-
ional MBF, short-axis slices were sectioned into 300- to
00-mg wedges and further subdivided into 3 transmural
ieces (i.e., endocardial, midwall, and epicardial). Myocar-
ial samples were weighed and counted in a gamma emis-
ion well spectrometer (PerkinElmer Inc.) along with ref-
rence blood samples. Blood flow was determined using
tandard techniques (12). Microsphere data from two ani-
als (one from each group) were not included in the
nalysis, due to problems with microsphere sampling.
On the basis of TTC staining and MBF, we assigned
amples to one of three regions: remote (TTC-positive
ocated opposite of the infarct); no-reflow (TTC-negative
ith MBF 50% of remote after reperfusion); and risk
egion (all samples with MBF 50% of remote during
cclusion). The no-reflow region was determined at 1 and
4 h after reperfusion.
To confirm necrosis extension and true infarct size on
easurements given by delayed perfusion images, micro-
phere ratio analysis was performed. In brief, baseline
icrosphere flow from infarcted and noninfarcted (remote)
reas were obtained in both groups (13). Infarct extension
hat implies continuing necrosis despite reperfusion was
efined as areas with an infarct-to-remote (infarct/remote)
pheres ratio equal to 1.0. Infarct/remote spheres ratio1.0
as considered microsphere dilution, and defined as infarct
xpansion. This event of expansion occurs due to cellular
dema and inflammation, rather than true necrosis. This
echnique was previously explained in detail (13).
tatistical analysis. Analyses were performed using
TATA software (College Station, Texas). All values are
xpressed as mean  SEM. Hemodynamic and MBF
arameters were analyzed by multiple measures analysis of
Table 1. Hemodynamic Measurements
Baseline
Heart rate (beats/min) 93  5
Systolic BP (mm Hg) 121  5
Mean BP (mm Hg) 100  6
MBF (ml/min/g)-IABC group 0.6  0.1
MBF (ml/min/g)-control group 0.72  0.1
MBF (%) 104  11
*p  0.001 vs. baseline.
BP  blood pressure; IABC  intra-aortic balloon coun
MBF (%)  percentage of myocardial blood flow in the infariance (ANOVA). Risk region sizes were compared be- mween groups using an unpaired t test. Linear regression
nalysis (Stata Corporation, College Station, Texas) was
sed to compare MRI measurements (no-reflow zone and
nfarct size) across time and between groups. We also used
obust regression technique to suppress distortions intro-
uced by outlying observations in the data set. Robust
egression, as previous described in details elsewhere
14,15), adjusts the weights applied to observations in an
terative fashion based upon the residuals from a prior
stimation step—the larger the residual the smaller the
eight. When no substantial changes to the weights can be
ound, the iterative procedure stops, and a different weight-
ng scheme is used. The entire procedure stops after the two
eighting strategies are exhausted. A level of p  0.05 was
onsidered statistically significant.
ESULTS
emodynamics and MBF. Seventeen animals were ran-
omized to either the IABC (n 9) or control (n 8) arms
f the experimental study. Three animals did not complete
he entire protocol, two animals in the IABC group and one
n control group. Table 1 summarizes hemodynamic and
lood flow parameters. Blood pressure decreased signifi-
antly with coronary occlusion (p  0.001), and returned to
aseline 24 h after reperfusion. Myocardial blood flow in the
nfarcted region was similar for both groups at baseline,
cclusion, or reperfusion (ANOVA; p NS). No differ-
nces in the size of the risk region were observed between
he two groups (36.1  3.8% IABC vs. 37.1  2.5%
ontrols; p  NS).
ostmortem analysis. There was a high degree of agree-
ent between the amount of MO measured by micro-
pheres and by MRI at 1 and 24 h after reperfusion (Fig. 1).
high correspondence for infarct location was demon-
trated between hyperenhanced areas observed on delayed
ontrast MRI and TTC-negative regions (Fig. 2). Infarct
ize by MRI (15.5 2%) had a high agreement with infarct
ize measured by TTC (12  2%) (Fig. 3).
ime course of microvascular obstruction. The time
ourse of changes in the extent of MO, assessed as hypoen-
ancement by first-pass MRI, was different between both
roups (Fig. 4). In the control group, the amount of MO
ncreased from 3.4  0.5% to 4.9  1.1% (as percent LV
cclusion
Reperfusion
(1 h)
Reperfusion
(24 h)
13  10 94  5 108  11
87  4* 88  7* 111  10
70  5* 70  6* 92  7
.26  0.1* 0.69  0.3 0.54  0.1
.26  0.1* 0.96  0.2 0.67  0.1
8.7  3 166  28 92  16
ation; MBF  myocardial blood flow in the infarcted area;
area relative to remote.O
1
0
0
terpulsass), while the IABC group demonstrated a reduction in
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4 h (p  0.001) (Fig. 5A). In a 24-h period of study, there
as an overall increase of 60  22% in MO extent on the
ontrol group, whereas a decrease of 10  10% was seen
ith intra-aortic balloon augmentation (p  0.001) (Fig.
B).
This different pattern of MO extent between groups was
onfirmed when analyzed inside the risk region and the
igure 1. Comparison of first-pass magnetic resonance imaging (MRI)
ypoenhancement (i.e., no-reflow) and microsphere blood flow 50%
elative to remote-region blood flow (A) at 1 and (B) 24 h after reperfusion.
alues are normalized to left ventricular (LV) mass.
igure 2. Short-axis magnetic resonance imaging (top) demonstrating infa
,3,5-triphenyltetrazolium chloride-staining in a representative animal.nfarcted myocardium. In the risk region, the amount of
yocardial tissue involved by MO showed a significant
ecrease with intra-aortic balloon augmentation (from 13.3
5.9% to 9.3  3.9%), whereas an important increase was
bserved in the control group (from 9.1  1.5% to 13.5 
.1%; p  0.05). The same pattern was noted when
nalyzed inside the infarcted myocardium, with the MO
xtent decrease in the IABC group (from 25.9 9% to 19.1
7.6%), and an increase in controls (from 27.1  4.6 to
9.4  4.2%; p  NS).
The above findings were confirmed by microsphere mea-
urements. The MO extent assessed as TTC-negative areas
ith MBF 50% of the remote evolved differently between
he groups. In the control group, an important increase in
O extension was noted (from 8.8  1.7% to 43.2 
1.1% of infarcted myocardium; p  0.05) (Fig. 5C). In
ontrast, the IABC group did not exhibit significant
hanges (from 21.3  7.1% to 25.8  14.7%; p  0.05 vs.
ontrol at 24 h). These findings support the importance of
alloon augmentation during the early phase of reperfusion.
nfarct size. Magnetic resonance imaging hyperenhanced
rea increased over 24 h in both groups (from 13.2  1.8%
o 15.5 2.1%, 1 and 24 h after reperfusion, p 0.05) (Fig.
). However, hyperenhanced region increase was signifi-
antly less in the IABC group than in control animals (13
cation and extent as a hyperenhancing region compared with postmortem
igure 3. Comparison of infarct size measured by delayed magnetic
esonance imaging (MRI) and postmortem analysis with 2,3,5-
riphenyltetrazolium chloride (TTC) staining 24 h after reperfusion. LV
eft ventricle.rct lo
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April 7, 2004:1291–8 Intra-Aortic Balloon Benefit on AMI.9% to 14.9  3.7% in the IABC group vs. 13.5  2% to
6.2 2% in controls, at 1 and 24 h, respectively; p 0.05)
Fig. 6). Also, relative to the risk region, the hyperenhanced
egion increased for the entire group from 1 to 24 h (36.9
.5% to 45  5.8%; p  0.01). In the IABC group,
yperenhanced area increase was less (36.2  8.6% to 40.8
9.3%) than in the control group (37.9  6.6% to 47 
.4%; p  NS).
To establish whether or not the above findings were due
o edema or necrosis, further microsphere ratio analysis was
erformed. In the control group, baseline microsphere ratio
nalysis demonstrated microsphere dilution and consequent
nfarct expansion (infarct/remote spheres ratio 1.0; 0.9 
.05). However, in the IABC group no infarct expansion
as noted (infarct/remote spheres ratio equal to 1.0 
.06).
ISCUSSION
his is the first study to demonstrate a reduction in the
ostinfarction progression of microvascular obstruction due
o IABC. Moreover, our results also demonstrate a reduc-
ion in postreperfusion infarct size expansion, which may be
elated to microvessel patency. Furthermore, our study
onfirms previous observations (3) with respect to the
agnitude of both MO and infarct size increase after
eperfusion in control animals.
O (no-reflow). Microvascular obstruction is a common
yproduct of reperfused acute MI (7,16–18). Recent studies
stimate that 25% to 30% of acute MI patients treated with
irect or rescue angioplasty develop significant microvessel
cclusion with deleterious effects on prognosis in terms of
reater LV remodeling (18,19), greater propensity for ma-
ignant arrhythmias (20), and adverse clinical outcomes
18,21). The degree of postreperfusion MO is directly
elated to the duration of coronary artery occlusion (17,22).
imilarly, the magnitude of MO is directly related to the
igure 4. Short-axis magnetic resonance image demonstrating example of
nimals in both groups. (A) A decrease in no-reflow extent in an
ntra-aortic balloon counterpulsation animal at 1 (left) and 24 h (right)
fter reperfusion. (B) An increase in no-reflow extent in a control animal
t same time points.mount of ischemic tissue during coronary occlusion (2). iignificantly, the process of microvascular damage is clearly
rogressive after epicardial artery reflow (3,16). While
everal previous studies have attributed the beneficial effects
f diverse interventions to a reduction in MO, this is the
rst experimental demonstration of a direct effect on the
rogression of no-reflow after infarction.
The mechanisms by which MO influences postinfarct
rognosis remain poorly understood. Several previous stud-
igure 5. Change in microvascular obstruction (MO) between the intra-
ortic balloon counterpulsation (IABC) (n 9) and control (n 8) groups
rom 1 to 24 h after reperfusion: (A) In the control group, MO increases
ver time, while in the IABC, MO decreases over 24 h (p  0.001). Grey
ars  control; black bars  IABC. (B) At 24 h of study period, an
ncrease of 60  22% on the control group was observed (as percent left
entricular mass), while, with intra-aortic balloon augmentation, a decrease
f 10  10% was noted. (C) Change in MO, evaluated as areas with
yocardial blood flow (MBF) 50% of the remote given as percent of
nfarcted region. In the control group, MO increases over time, while, in
he IABC, no important change is observed (p  0.05 vs. control at 24 h).
R  no-reflow.es established a link between MO and greater LV remod-
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Intra-Aortic Balloon Benefit on AMI April 7, 2004:1291–8ling over and above the influence of infarct size (18,21).
ore recent experimental work has demonstrated that this
ink may be mediated by an increase in infarct stiffness and
yocardial stunning within regions involved by MO
19,21). Concurrent with changes in local material proper-
ies is increased dysfunction of noninfarcted regions adja-
ent to the infarct border (23). Interestingly, these findings
orrelate with recently published clinical observations relat-
ng a larger extent of the no-reflow region to worse diastolic
unction in patients matched by infarct size (22). Other
linical studies have related microvascular damage to a
reater incidence of malignant arrhythmias after infarction
19). In effect, much has been recently written on strategies
o decrease MO in order to prolong survival and improve
he quality of life of patients who suffer acute MI (3,5). The
ealization that survival improvements have not matched the
efinement of therapeutic strategies designed to establish
nd secure large vessel coronary reflow underscores the need
o focus attention on the distal microvasculature (24).
Intra-aortic balloon counterpulsation is currently used by
any cardiovascular interventionalists to empirically treat
atients with incapability to restore normal coronary flow
Thrombolysis in Myocardial Infarction-3) after revascular-
zation. While the present study documents its inhibitory
ffect on the natural course of postreperfusion no-reflow
ugmentation, it does not substitute for a controlled clinical
rial in post-MI patients with documented microvascular
O. The many other factors involved in the clinical
tilization of any therapeutic modality may confound and
ven negate the beneficial effects of IABC on no-reflow and
nfarct size increase demonstrated in our study. In addition,
he mechanisms underlying the inhibitory effect of IABC on
O remain unknown. The possibility that enhanced mi-
rovessel flow prevents intracapillary cell adhesion and
onsequent transmigration of inflammatory cells into the
nterstitial space is a potential explanation for the differences
n the rate of microvessel occlusion observed in the two
roups of animals. This potential mechanism is also invoked
o explain the beneficial effects of adenosine and other tissue
asodilators shown to improve outcomes in coronary inter-
igure 6. Infarct expansion measured by delayed magnetic resonance
maging (MRI) in intra-aortic balloon counterpulsation (IABC) (n  9)
nd control (n  8) animals increased over 24 h of reperfusion in both
roups (p  0.03). Infarct expansion was decreased in IABC relative to
ontrols (p  0.04). p  0.04 vs. control. LV  left ventricular.entions (25). Other possibilities relate to the potential offects of IABC on reperfusion injury, ventricular load, or
nflammation by yet unknown mechanisms. The previously
emonstrated beneficial effect of IABC on patients with
ostinfarct cardiogenic shock could be, in part, due to
ABC’s effect on reducing MO, given that patients in shock
requently have large territories of injured myocardial tissue
aused by prolonged epicardial coronary occlusion.
nfarct size. Previous research has demonstrated an in-
rease in infarct size over time, described as a progressive
avefront of necrosis away from the infarct core (16).
owever, the differentiation between true necrosis and
xpansion due to edema and the inflammatory process still
oses a significant challenge to clinical practice.
Using MRI, our group has documented this pattern of
ncrease delayed hyperenhancement areas, along with mi-
rovascular obstruction in a canine model (3). In the present
tudy, infarct size was measured by MRI, and necrosis
xtension was confirmed with infarct/remote spheres ratio
iven by microsphere analysis (13). There was a significant
ncrease in the hyperenhanced region in the control animals
ompared with the IABC group. In spite of this, the
nfarct/remote spheres analysis did not confirm the presence
f necrosis (infarct extension). The control group demon-
trated infarct expansion (infarct/remote spheres ratio1.0;
.9  0.05), and, in the IABC group, no infarct expansion
as noted (infarct/remote spheres ratio 1.0  0.06). This
bsence of infarct expansion, in 24 h of study, was associated
ith a decrease in MO progression. The presence of infarct
xpansion in the control group does not allow us to draw
ny conclusions regarding differences in necrosis extension
etween groups. However, these results suggest a cause/
ffect relationship between MO and cellular edema devel-
pment. Future studies are necessary to clarify this cause/
ffect relationship.
Large clinical trials testing the effect of IABC on clinical
utcomes have provided contradictory results (6,26). While
ABC is clearly beneficial in patients with large MIs
ccompanied by cardiogenic shock (6), another trial that
nrolled a large variety of postinfarction patients failed to
emonstrate a clear-cut benefit of IABC over conventional
herapy (26). None of the previous trials measured the effect
f balloon augmentation directly in the infarcted area, and,
hus, it is difficult to make a direct comparison with the
resent study. The discrepant results from different trials
ould be due to the possibility that patients with large
nfarcts benefit more from IABC therapy than patients with
maller infarcts. The results from our study suggest that
linical trials in patients with large infarcts should be
econsidered, given the potential for reducing ultimate
nfarct expansion, possible due to an improvement in
yocardial stiffness after acute MI.
The mechanisms of protection relative to infarct expan-
ion that are associated with IABC therapy also remain
nclear. The idea that the MO could further expend the
nfarcted region is not new and has been intensely debated
ver the last three decades. Areas of MO are commonly
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April 7, 2004:1291–8 Intra-Aortic Balloon Benefit on AMIoncentrated at the infarct core where ischemia was greatest
t the time of coronary occlusion and cell death is wide-
pread (3,16,22). In addition, widespread microvessel dam-
ge could impair the delivery of nutrients and removal of
oxins to and from the infarct penumbra, promoting inflam-
atory process with consequent infarct expansion and a
orse prognosis. However, our study documents the asso-
iation between both phenomena in an experimentally
ontrolled trial of IABC.
ethodological considerations. The most positive meth-
dologic feature of this study is its randomized design.
andomization was performed after the infarct-related
rtery was occluded but before it was reopened by balloon
eflation. Second, the two main determinants of myocardial
njury (occlusion time and risk region size) were controlled
igorously in this experimental design. Third, infarct size
nd extent of no-reflow were quantified by objective criteria
nd blindly, relative to group assignment.
The measurement of microvascular obstruction extent
epends on the criteria chosen to define microvessel occlu-
ion by different methods (27). We chose a threshold of
0% or less relative to remote myocardial flow to allow for
omparability with previously published data. At present,
here is no definitive data to identify the ideal delay time
fter contrast injection for measurement of MO extent by
RI. Due to the dynamics of the contrast agent, MO
ecreases over time after contrast. Problems with measure-
ents would be anticipated if images in the control group
ere acquired at slightly different postcontrast times, com-
ared with the IABC group. In this study, measurements
ere performed using definitive criteria. Microvascular ob-
truction extent was defined as the largest hypoenhanced
rea at the first minute after contrast injection, as agreed by
wo observers blinded to the randomization. We found a
ery good correlation between no-reflow defined by micro-
pheres and MRI, as previously documented in our earlier
ork (5,28). Also, much has been written about infarct size
easurements made by MRI (3,5,22,28). This noninvasive,
n vivo method is undoubtedly reliable and consistently
roduces overestimation when compared with TTC ex vivo,
rimarily because of partial volume effects (28). To control
he influence of a possible partial volume effect and to
ermit a clear interpretation of our results, further analyses-
ased microsphere ratio analysis was performed.
onclusions. In conclusion, this study documents a reduc-
ion in the process of microvascular obstruction produced by
ABC in experimental acute MI. In addition, the study
emonstrates a concomitant reduction in infarcted area
xpansion caused by IABC. Finally, the study confirms the
ndings of previous studies, which show that both micro-
ascular obstruction and infarcted area expansion progress
ignificantly after reperfusion following acute MI. These
ndings have important implications to our understanding
f the pathophysiology of acute MI, and may impact the
esign of future strategies to further limit left ventricular
amage beyond reperfusion in patients with this condition.cknowledgments
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